Fig. 5From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II studyOverall survival of gemcitabine-mono (blue curve) and cisplatin- gemcitabine (green curve) patients. Patients receiving cisplatin plus gemcitabine had a median OS of 36.9 months (95% CI 22.1–51.7), and patients receiving gemcitabine alone had a median survival of 46.9 months (95% CI 17.5–76.3)Back to article page